EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction.

about

EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction.

Item

http://www.wikidata.org/entity/Q37709182

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

EGFR kinase inhibitors and gas ...... of potential drug interaction.

@en

EGFR kinase inhibitors and gas ...... of potential drug interaction.

@nl

type

Item

label

EGFR kinase inhibitors and gas ...... of potential drug interaction.

@en

EGFR kinase inhibitors and gas ...... of potential drug interaction.

@nl

prefLabel

EGFR kinase inhibitors and gas ...... of potential drug interaction.

@en

EGFR kinase inhibitors and gas ...... of potential drug interaction.

@nl

P1476

EGFR kinase inhibitors and gas ...... of potential drug interaction

@en

P2093

Atasha Asmat

http://www.w3.org/2001/XMLSchema#string

Brendan Pang

http://www.w3.org/2001/XMLSchema#string

En Yun Loy

http://www.w3.org/2001/XMLSchema#string

Huili Zheng

http://www.w3.org/2001/XMLSchema#string

Nesaretnam Barr Kumarakulasinghe

http://www.w3.org/2001/XMLSchema#string

Ross Andrew Soo

http://www.w3.org/2001/XMLSchema#string

Yu Yang Soon

http://www.w3.org/2001/XMLSchema#string

P2860

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.

Serum concentrations of Erlotinib at a dose of 25 mg daily.

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Erlotinib and pantoprazole: a relevant interaction or not?

P304

85542-85550

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.13458

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas L Syn

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27907909

http://www.w3.org/2001/XMLSchema#string

P921

Base de dados

P932

5356756

http://www.w3.org/2001/XMLSchema#string